The present disclosure provides a genetically modified mouse comprising a genomic nucleic acid encoding human APOE4, a genomic nucleic acid encoding mouse TREM2 modified to include a R47H substitution, and at least one genomic modification selected from the group consisting of: (a) a genomic nucleic acid encoding mouse ABCA7 modified to include an A 1541 G substitution; (b) a genomic nucleic acid encoding mouse APP modified to include G601R, F606Y, and R609H substitutions; (c) a genomic nucleic acid encoding mouse PLCG2 modified to include a M28L substitution; (d) a genomic nucleic acid encoding mouse MTHFR modified to include a A262V substitution; (e) an inactivated Ceacam1 allele; and (f) an inactivated Il1rap allele. Methods of producing the genetically modified mouse and methods of using the genetically modified mouse are also provided.

The present invention relates to a composition for treating neuroinflammatory disease comprising a complement component 8 gamma protein or a fragment thereof, and more particularly, to use for treating neuroinflammatory disease of a complement component 8 gamma protein or a fragment thereof which exhibits an effect of reducing the expression of inflammatory cytokines in microglia.

The composition of the present invention has effects of reducing Alzheimer's abnormal behavior patterns and reducing the secretion of neuroinflammatory cytokines in brain microglia and thus can be very usefully used for development of an agent for preventing or treating neuroinflammatory disease.

The present invention relates to a vector comprising a nucleic acid sequence that encodes the APP protein and/or the PS1 protein or variants thereof. The invention also relates to a method for inducing the Alzheimer's disease in an animal using the vector of the invention and to animal model having the Alzheimer's disease obtained by said method.

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

[Problem] To provide: an actually effective therapeutic method which is for dementia of Alzheimer's disease, and which is a causal treatment rather than a symptomatic treatment; and a therapeutic substance for dementia of Alzheimer's disease. [Solution] This substance alleviates symptoms such as dementia of Alzheimer's disease by overexpressing a microtubule-associated protein 1B gene in intracerebral neurons. In addition, as methods to solve the problem above, there are mainly two methods: a method for intracerebral administration of a gene therapy vector bound to a microtubule-associated protein 1B gene; and a method for binding a microtubule-associated protein 1B gene to a blood-brain barrier (BBB) permeable nanomachine and administering intravascularly.

This document provides methods and materials involved in treating mammals having a neurological disorder in the brain (e.g., Alzheimer's disease). For example, methods and materials for administering a composition including exogenous nucleic acid encoding a NeuroD1 polypeptide to a mammal having a neurological disorder in the brain are provided.

The present disclosure provides agents, compositions, and methods for inhibiting necroptosis in the brains of subjects in need thereof. In some embodiments, agents, compositions, and methods provided herein are useful for treating necroptosis-mediated neurovascular or neurodegenerative diseases or disorders, e.g., Alzheimer's disease.

Compositions and methods to prevent, inhibit or treat a disease or disorder associated with expression of APOE4 in a mammal are provided.

The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.

Provided is an Alzheimer's disease rat model or a tissue or cell thereof, which comprises a chimeric APP gene encoding a modified APP and use thereof.